(Q46864710)

25 December 2017

title

Aldosterone antagonists in the treatment of heart failure. (English)

1 reference

25 December 2017

author name string

Todd R Marcy

series ordinal

1

1 reference

25 December 2017

Toni L Ripley

series ordinal

2

1 reference

25 December 2017

language of work or name

1 reference

1 January 2006

1 reference

25 December 2017

American Journal of Health-System Pharmacy

published in

1 reference

25 December 2017

volume

63

1 reference

25 December 2017

issue

1

1 reference

25 December 2017

page(s)

49-58

1 reference

25 December 2017

Long-Term Trends in the Incidence of and Survival with Heart Failure

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Trends in Heart Failure Incidence and Survival in a Community-Based Population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Guidelines for the diagnosis and treatment of chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Aldosterone in congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Production of aldosterone in isolated rat blood vessels

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Vascular aldosterone in genetically hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Aldosterone induces a vascular inflammatory phenotype in the rat heart

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Biological determinants of aldosterone-induced cardiac fibrosis in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Potentiation of angiotensin II action by corticosteroids in vascular tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

PAI-1, fibrosis, and the elusive provisional fibrin matrix

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

The effect of digoxin on mortality and morbidity in patients with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Integrating traditional and emerging treatment options in heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Pharmacokinetics of diuretics in geriatric patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Eplerenone: cardiovascular protection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

The hospital anxiety and depression scale

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

The safety of spironolactone treatment in patients with heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Serious adverse events experienced by patients with chronic heart failure taking spironolactone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Pharmacotherapy for heart failure in patients with renal insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Diabetes may be independent risk factor for hyperkalaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Hyperkalemia and hyporeninemic hypoaldosteronism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

High cytosolic pH inhibits Ca uptake by Myxicola axon mitochondria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Studies on the mechanism of trimethoprim-induced hyperkalemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Heparin-induced aldosterone suppression and hyperkalemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Efficacy and tolerance of spironolactone in essential hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050041

31 March 2020

Identifiers

DOI

10.2146/AJHP050041

1 reference

25 December 2017

1 reference

25 December 2017